HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Viking Therapeutics (VKTX) and raises the price target from $33 to $90.
February 27, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics' price target was raised from $33 to $90 by HC Wainwright & Co., with a maintained Buy rating.
The significant increase in the price target by a reputable analyst firm, along with the maintained Buy rating, suggests a strong bullish outlook for Viking Therapeutics. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100